Can-C™ Eye-drops Receive Patent- Recognised Leader In The Field

We’re pleased to announce that the Can-C brand has been recognised by the US patent office as original and unique since its patent came into force at the end of 2010.

Dr. Mark Babizhayev its inventor at Innovative Vision Products commented; “it is great news that Can-C has been granted its patent license in the USA after many years of patent pending. It is recognition of all our work in studying, testing and proving that Can-C is efficacious and of great value to the aging community.”

Dr. Babizhayev went on to say; “we expect further patent applications to be granted both in the USA, Europe and in Japan and these will help to enforce the true, tried and tested eye-drops in the marketplace at large.”

IAS is delighted to have been at the forefront of this technology being as it is the worldwide exclusive distribution agent; its Vice President, Phil Micans said “it’s hard for me to believe that we launched it in 2003 more than 8 years ago; whilst we know it has helped many thousands of people and even dogs! We also appreciate that the vast majority of the public are still unaware that they can prevent, delay and even reverse their cataract with an eye-drop!” Phil continued “Can-C represents just the kind of technology that we like to bring to the fore, it’s new, scientifically and clinically proven and yet perhaps still many years away from the mainstream medical marketplace, I like to think of IAS as being on the cutting-edge, Can-C is just one of our examples of us doing just that.”

Perhaps it’s worth reminding ourselves of the advantages of Can-C and why cataract is such a universal and difficult problem.

Cataracts

Today, cataract surgery is the most commonly performed surgical procedure in the world, and an amazing 43% of all visits to ophthalmologists are because of cataract. Perhaps this isn’t surprising when you realize that 25% of people over the age of 65 have a cataract!

1.35 million cataract operations are performed every year in the USA and Medicare estimates the annual cost at $3.5 billion! There is no doubt that cataract is a major age-related disease.

With so many people suffering from what is known as senile cataract, it appears that it may not to possible to train enough surgeons. In-fact, it looks likely that the number of people with serious eye-problems due to cataract will increase dramatically worldwide.

Cataract surgery

What is also not well known is that 30% to 50% of all patients who undergo cataract surgery develop complications within two years. Since the number of cataract operations is so large, even a small percentage of problems represent a significant number of people. About 2% of the 1.35 million, (or approximately 27,000 people), just in the US each year, develop serious complications as a result of cataract surgery.

Besides these possible complications, an artificial lens just does not have the overall optical qualities of a natural lens.

It was these arguments and statistics, that made scientists in Moscow, look for an alternative that would be a lot simpler and cheaper. The result of more than 10-years of their research is a remarkable breakthrough that holds great promise for those concerned about senile cataract.

The anti-cataract eye-drops

The Russian science group is known as Innovative Vision Products and their experiments show that cataract’s are formed in the aging eye, when the eye’s anti-oxidant levels became low, which tends to occur much more the older we become. In numerous studies, (which have been published in western clinical Journals), they have discovered that the eye relies heavily upon an anti-oxidant known as carnosine.

The principal scientist behind the research, Dr. Mark Babizhayev stated; “We experimented with many different forms of carnosine, but the one that has proved itself to be safe and effective for long-term continuous use is known as N-acetylcarnosine. Our research has managed to develop a specific purity and formula of this anti-oxidant and anti-glycation agent. Our published clinical results of a 2-year human study have shown that we can effectively slow and even reverse cataract in the human eye with our material, which is a natural eye-drop.”

Dr. Babizhayev first released details of his research to a western audience in Europe, at the 2003 Monte Carlo Anti-Aging Conference, and many of the researchers and physicians present there recognised that this development is a major leap forward in the treatment and possible prevention of senile cataract, which will benefit millions of people.

European trials

To date, the eye-drops, which are known under the brand name of Can-C, have had a very significant success rate for patients within 3-6 months of treatment. Dr. Babizhayev said; “In the trials there has been an improvement in eye-quality for all tested persons, with the very best results appearing in those who have had cataract for the shorter periods of time.”

There is no doubt, that these are remarkable results, because previously the best that could normally be expected would be a halt to the progression of the cataract and usually its continual worsening.

One of the major Russian studies documented the changes in eye lens clarity over a 6 to 24 month period for 49 volunteers. Their average age was 65 and all of them suffered from senile cataract.

The patients received either Can-C eye-drops, or a placebo, at 2-drops twice a day into the eye. The patients’ eyes were then tested at regular periods. At 6-months, 88.9% of all eyes treated with Can-C eye-drops had an improvement of glare sensitivity, 41.5% of all eyes treated had a significant improvement of the transmissivity of the lens, but perhaps most importantly 90% of the eyes treated showed an improvement in visual acuity. Meanwhile, in the placebo (control) group there was little change in eye quality at 6-months and a gradual deterioration at 12 to 24 months.

Importantly, this study also showed that at 24-months the patients using Can-C eye-drops, (who already had significant improvement to the quality of their eyesight), sustained these results with continued use of the drops.

Plus, it was noted that apart from some mild stinging sensations in rare cases, no other serious side effects were noted throughout the 2-year period. Furthermore, as of 2011 Can-C has been on sale in some markets for several years and many thousands of people (and indeed dogs too!) have used the drops and no reports of any serious side effects have been reported.

Conclusion

Cataract is such a widespread age-related affliction and Can-C eye-drops appear to be a breakthrough for the treatment, and maybe even the prevention of cataract.

It is not surprising, that those who know about this work within the medical community, suspect that these eye-drops are going to have a major impact on the way that cataract is thought about, dealt with and controlled.